MedTrace Logo

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

NCT04306237 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-11-10

No results posted yet for this study

Summary

The objectives of the study are to assess the safety, tolerability, and potential efficacy of IMB-1018972 on patients with refractory angina. Study will assess functional capacity employing a modified Bruce Protocol treadmill ETT, patient reports of angina symptoms via an electronic diary, and activity using an accelerometer.

Conditions

  • Refractory Angina

Interventions

DRUG

IMB-1018972

IMB-1018972 200 mg tablet for oral administration

DRUG

Placebo oral tablet

Matched placebo tablet for oral administration

Sponsors & Collaborators

  • Imbria Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Paul Chamberlin, MD · Imbria Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2025-02-28
Completion
2025-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04306237 on ClinicalTrials.gov